10239-34-6

Basic information

• Product Name: N,N'-Dibenzyl-1,3-propanediamine
• Synonyms: N,N'-Dibenzyl-1,3-propanediamine;n,n'-bis(phenylmethyl)-1,3-propanediamine;1,3-PROPANEDIAMINE, N,N'-BIS(PHENYLMETHYL)-;N,N'-bis(benzyl)-1,3-diaminopropane;N,N'-Dibenzyl-1,3-pr;N1,N1-Dibenzylpropane-1,3-diaMine;benzyl[3-(benzylaMino)propyl]aMine;N1,N3-Dibenzylpropane-1,3-diaMine
• CAS NO: 10239-34-6
• Molecular Formula: C₁₇H₂₂N₂
• Molecular Weight: 254.37
• Product Categories: Polyamines
• Mol File: 10239-34-6.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 389.8 °C at 760 mmHg
• Flash Point: 230.2 °C
• Appearance: /
• Density: 1.017 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 9.73±0.19(Predicted)
• CAS DataBase Reference: N,N'-Dibenzyl-1,3-propanediamine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N'-Dibenzyl-1,3-propanediamine(10239-34-6)
• EPA Substance Registry System: N,N'-Dibenzyl-1,3-propanediamine(10239-34-6)

Safety Data

• Hazardous Substances Data: 10239-34-6(Hazardous Substances Data)

Usage

Uses

N,N''-Dibenzyl-1,3-diaminopropane is a hepatitis C virus inhibitor.

Upstream product

• 63674-16-8 N,N'-bisbenzylidene-1,3-diaminopropane 
• 921-01-7 rac-cysteine 
• 1606142-71-5 N,N'-(propane-1,3-diyl)bis(N-benzyl-2,4-dinitrobenzenesulfonamide) 
• 100-39-0 benzyl bromide 
• 100-52-7 benzaldehyde 
• 102950-52-7 1,3-dibenzyl-2-phenyl-hexahydro-pyrimidine 
• 98-88-4 benzoyl chloride 
• 63674-16-8 N,N'-Bis-[1-phenyl-meth-(E)-ylidene]-propane-1,3-diamine 
• 100-44-7 benzyl chloride 
• 109-76-2 Trimethylenediamine 
• 109-64-8 1,3-dibromo-propane 
• 100-46-9 benzylamine 
• 68388-03-4 N,N'-(propane-1,3-diyl)dibenzamide 

Downstream Products

• 102949-61-1 1,3-dibenzyl-2-(4-chloro-phenyl)-hexahydro-pyrimidine 
• 107886-56-6 N,N'-dibenzyl-N-(3-phthalimidopropyl)-1,3-diaminopropane 
• 1048001-97-3 1-[(2-nitrophenyl)sulfonyl]-1,5,9,13-tetraazacyclohexadecane 
• 1061274-68-7 6,10-dibenzyl-N-butyl-4,11,14-trioxo-3,6,10,13-tetraazapentadecan-1-amide 
• 1061274-58-5 2-(acetylamino)-N-benzyl-N-(3-{benzyl[2-(cyclohexylamino)-2-oxoethyl]amino}propyl)acetamide 
• 1061274-61-0 3-(acetylamino)-N-benzyl-N-(3-{benzyl[2-(butylamino)-2-oxoethyl]amino}propyl)propanamide 
• 1061274-69-8 3-(acetylamino)-N-benzyl-N-(3-{benzyl[2-(ethylamino)-2-oxoethyl]amino}propyl)propanamide 
• 1061274-66-5 4-(acetylamino)-N-benzyl-N-(3-{benzyl[2-(butylamino)-2-oxoethyl]amino}propyl)butanamide 
• 1061274-57-4 2-(acetylamino)-N-benzyl-N-(3-{benzyl[2-(dodecylamino)-2-oxoethyl]amino}propyl)acetamide 
• 102233-94-3 N,N'-1,3-bisphenylmethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
• 65838-45-1 N,N'-(cyclohexane-1,2-diyl)bis(1-phenylmethanimine) 
• 1043893-48-6 cis-(1R,2S)-N,N'-dibenzylcyclohexane-1,2-diamine 

Relevant articles and documents

A minimalistic approach to develop new anti-apicomplexa polyamines analogs

The development of new chemical entities against the major diseases caused by parasites is highly desired. A library of thirty diamines analogs following a minimalist approach and supported by chemoinformatics tools have been prepared and evaluated agains

Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study

Human myeloperoxidase (MPO) plays an important role in innate immunity but also aggravates tissue damage by oxidation of biomolecules at sites of inflammation. As a result from a recent high-throughput virtual screening approach for MPO inhibitors, bis-2,2′-[(dihydro-1,3(2H,4H) pyrimidinediyl)bis(methylene)]phenol was detected as a promising lead compound for inhibition of the MPO-typical two-electron oxidation of chloride to hypochlorous acid (IC50= 0.5 μM). In the present pharmacomodulation study, 37 derivatives of this lead compound were designed and synthesized driven by comprehensive docking studies and the impact on the chlorination activity of MPO. We describe the structural requirements for optimum (i) binding to the heme periphery and (ii) inhibition capacity. Finally, the best three inhibitors (bis-arylalkylamine derivatives) were probed for interaction with the MPO redox intermediates Compound I and Compound II. Determined apparent bimolecular rate constants together with determination of reduction potential and nucleophilicity of the selected compounds allowed us to propose a mechanism of inhibition. The best inhibitor was found to promote the accumulation of inactive form of MPO-Compound II and has IC50= 54 nM, demonstrating the successful approach of the drug design. Due to the similarity of ligand interactions between MPO and serotonine transporter, the selectivity of this inhibitor was also tested on the serotonin transporter providing a selectivity index of 14 (KiSERT/IC50MPO).

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kirl.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.